ProceedingsPROCEEDINGS 1 SYMPOSIUM COMMITEE Andy Durham (Liphook Equine Hospital, UK) Nicholas Frank (Tufts University, USA) Catherine McGowan (University of Liverpool, UK) Harold Schott (Michigan State University, USA) Allison Stewart (University of Queensland, AUS) Melody de Laat (Queensland University of Technology, AUS) HOSTED BY PROCEEDINGS 3 FOREWORD Dear Delegate, We are very happy to welcome you to the fourth Global Equine Endocrine Symposium at Gut Ising (Germany), hosted by Boehringer Ingelheim. As a community within the equine world, we are dedicated to raising awareness, to better ­understanding­and­to­developing­a­standard­of­care­for­horses­suffering­from­EMS,­PPID­and­ other misunderstood endocrinopathies to all equine stakeholders. Our program this year will focus on a number of areas: • Epidemiology of equine endocrine diseases; ­ •­ ­Aetiopathogenesis­of­pituitary­pars­intermedia­dysfunction­(PPID)­and­equine­ metabolic syndrome (EMS); ­ •­ Diagnosis­of­endocrine­diseases; ­ •­ Treatment­and­monitoring­of­PPID, • Management of obesity and EMS, and • Endocrinopathic laminitis and insulin dysregulation. We­hope­that­the­symposium­will­succeed­at­bringing­the­scientific­community­together­and­further­ drive research and knowledge about endocrine diseases. Finally yet importantly, we hope that you enjoy this symposium. Sincerely, Boehringer Ingelheim and the Scientific Committee 4 4th Global Equine Endocrine Symposium 2020 CONTENTS Symposium Commitee ................................................................................................................................................................2 Foreword .......................................................................................................................................................................................3 Contents ...................................................................................................................................................................................4 / 5 Tatum:­A­cross-sectional­study­of­horses­diagnosed­with­PPID­in­the­United­Kingdom:­ Demographics,­management­and­healthcare­ .................................................................................................................6 Schott: Steroid­hormone­profiles­of­horses­with­PPID ..................................................................................................7 Meyer: A systematic review and meta-analysis on the diagnostic accuracy of baseline ACTH­for­the­diagnosis­of­PPID­in­adult­horses­and­ponies­ ..........................................................................................8 Durham:­Temporally-specific­diagnostic­thresholds­for­plasma­ACTH­in­the­horse­ ..............................................10 Bailey: Seasonal variation in ACTH concentrations and dexamethasone suppression tests in ponies and andalusian horses compared with standardbreds .....................................................................12 Haffner:­The­effect­of­trailering­and­dentistry­on­resting­acth­concentration­in­horses­ .....................................13 Bamford: Comparison of autumnal ACTH concentrations between apparently healthy horses and ponies .....14 Potier: The­effect­of­latitude­and­breed­on­circannual­ACTH­concentrations­in­the­UK­ ......................................15 Bertin: The­effect­of­freeze-thaw­cycles­on­the­determination­of­immunoreactive­ACTH­ ..................................18 Banse:­ACTH­stability­in­frozen­equine­plasma­ ............................................................................................................19 Grubbs:­Development­and­evaluation­of­a­clinical­sign­scoring­system­for­PPID­in­horses ...................................20 Banse:­Comparison­of­muscle­mass­and­skeletal­muscle­proteolysis­in­aged­horses­with­and­without­PPID ...21 Bertin: The­repeatability­of­the­TRH­stimulation­test­for­the­diagnosis­of­PPID­ ...................................................22 Hoffman: The­TRH­procedure­produces­repeatable­ACTH­concentrations­in­PPID-negative­ and­PPID-positive­horses ....................................................................................................................................................23 Sanchez-Londoño:­Evaluation­of­different­doses­of­TRH­in­miniature­horses­ ......................................................24 Schorn:­Comparison­of­two­TRH­doses­in­PPID­patients­ ............................................................................................25 Haffner:­Duration­of­effectiveness­of­frozen/thawed­TRH­to­stimulate­ACTH­release­in­horses­ ......................26 Gough: Is there merit in utilising the TRH stimulation test in horses with an equivocal ACTH ............................27 Stewart: ACTH­concentrations­following­TRH­stimulation­in­horses:­effect­of­sample­handling­ on ACTH following TRH stimulation in horses ...............................................................................................................28 Knowles:­Elution­of­endogenous­CLIP­from­an­ACTH­assay­capture­antibody­ .......................................................29 Potier: Circannual pattern of ACTH, insulin and glucose concentrations in horses and ponies ..........................31 Pollard:­Investigating­the­epidemiology­of­PPID­in­horses/ponies­enrolled­in­a­laminitis­cohort­ study in Great Britain ........................................................................................................................................................33 Steel:­Management­of­equine­PPID­in­veterinary­practice:­a­clinical­audit­ .............................................................34 Menzies-Gow:­The­effect­of­pergolide­dosing­compliance­on­the­laboratory­control­of­PPID­ ..........................36 Tatum:­A­cross-sectional­study­of­horses­diagnosed­with­PPID­in­the­United­Kingdom:­ Treatment practices and factors associated with quality of life ................................................................................39 Hart:­Pharmacokinetics­of­pergolide­mesylate­in­donkeys­ .....................................................................................40 PROCEEDINGS 5 Schorn:­ACTH­after­TRH­stimulation­in­PPID­patients­treated­with­pergolide­for­6-8­weeks ...............................41 Schott:­Owner­assessment­of­long-term­treatment­of­PPID ......................................................................................42 Carslake:­Equine­metabolic­syndrome­in­native­United­Kingdom­ponies­and­cobs:­Prevalence­and­risk­factors ...43 Warnken: The­effect­of­fasting­versus­no-fasting­on­results­of­oral­testing­for­insulin­ dysregulation with glycemic carbohydrates ..................................................................................................................44 De Laat: Glucose­stimulates­GLP-2­secretion­from­equine­small­intestine­ .............................................................45 Vaughn: Associations between systemic oxidative stress and endocrine parameters in horses and ponies .....46 Coleman:­Fecal­extract­from­obese­horses­induces­inflammation­in­vitro...............................................................47 Morgan: The equine pancreas in chronic hyperinsulinaemia .....................................................................................48 Macon: Insulinemic responses to non-structural carbohydrates and crude protein in varying concentrates in healthy and insulin dysregulated horses ...........................................................................................49 Macon:­Insulin­dysregulated­horses:­responses­to­varying­oral­sugar­and­fasting­to­the­oral­sugar­test ...........51 Frers: Insulin signaling of liver and adipose tissue in insulin-dysregulated horses after oral glucose administration ..............................................................................................................................................52 Brojer: Comparisons of basal insulin concentrations, oral sugar test results and euglycemic-hyperinsulinemic clamp measurements in horses ...................................................................................53 Delarocque:­Plasma­metabolome­of­horses­during­oral­glucose­tests­ ...................................................................54 Carslake: Evaluation of three dynamic oral carbohydrate tests for insulin dysregulation in ponies ..................55 Warnken:­Nationwide­comparison­of­different­methods­used­for­measurement­of­insulin­ in veterinary laboratories in Germany .............................................................................................................................56 Ireland:­Translating­research­in­to­practice:­adoption­of­endocrine­diagnostic­testing­in­cases­of­laminitis .....57 Winter: Is the magnesium metabolism altered in horses with insulin dysregulation .............................................59 Toribio: Dynamics­of­incretins­and­insulin­in­hospitalized­foals­ ................................................................................60 Karikoski: Effects­of­alpha­2-adrenoceptor­agonism­and­antagonism­on­blood­glucose­ concentration in horses with normal insulin regulation ..............................................................................................61 Stewart:­Factors­associated­with­critical­illness­related­corticosteroid­insufficiency­(CIRCI)­in­adult­horses .......62 Toribio: Sex­hormone­concentrations­differ­between­healthy­and­critically­ill­foals­